Adjuvant Treatment With a Glycoprotein IIb/IIIa Receptor Inhibitor Increases the Therapeutic Window for Low-Dose Tissue Plasminogen Activator Administration in a Rat Model of Embolic Stroke
- 10 June 2003
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 107 (22), 2837-2843
- https://doi.org/10.1161/01.cir.0000068374.57764.eb
Abstract
Background— Platelet aggregation and fibrin deposition are key events leading to microvascular thrombosis and progressive impairment of downstream microvascular perfusion after stroke. We tested the hypothesis that inhibition of platelet function with a GP IIb/IIIa receptor antagonist would increase the efficacy and safety and increase the time window for thrombolytic therapy for stroke with full- and half-dose tissue plasminogen activator (tPA). Methods and Results— Rats were subjected to embolic middle cerebral artery occlusion. Four hours after ischemia, rats were treated with 7E3 F(ab′) 2 (6 mg/kg) in combination with tPA at doses of 10 and 5 mg/kg, tPA alone at a dose of 10 or 5 mg/kg, 7E3 F(ab′) 2 (6 mg/kg) alone, or saline. Combination treatment with 7E3 F(ab′) 2 and tPA (full- or half-dose) significantly ( P 2 or tPA (full- or half-dose) alone did not reduce infarct volume. Quantitative measurements of cerebral microvessels perfused by FITC-dextran revealed that combination treatment with 7E3 F(ab′) 2 and full-dose tPA significantly ( P 2 in combination with full-dose tPA significantly ( P Conclusions— Combination treatment with 7E3 F(ab′) 2 with full- and half-dose tPA at 4 hours after ischemia significantly reduces infarct volume and improves neurological outcome. Enhancement of patency and integrity of cerebral microvessels most likely contributes to the benefits observed with this combination therapy.This publication has 17 references indexed in Scilit:
- Glycoprotein IIb/IIIa Antagonist, Murine 7E3 F(ab′)2, and Tissue Plasminogen Activator in Focal Ischemia: Evaluation of Efficacy and Risk of Hemorrhage with Combination TherapyJournal of Cerebral Blood Flow & Metabolism, 2002
- Dynamic platelet accumulation at the site of the occluded middle cerebral artery and in downstream microvessels is associated with loss of microvascular integrity after embolic middle cerebral artery occlusionBrain Research, 2001
- Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14European Heart Journal, 2000
- VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brainJCI Insight, 2000
- Release of gelatinase A during platelet activation mediates aggregationNature, 1997
- Tissue Plasminogen Activator for Acute Ischemic StrokeThe New England Journal of Medicine, 1995
- Reocclusion after thrombolytic therapyBlood Coagulation & Fibrinolysis, 1993
- Coronary Thrombolysis: Streptokinase or Recombinant Tissue-Type Plasminogen Activator?Annals of Internal Medicine, 1990
- Seizures and recovery from experimental brain damageExperimental Neurology, 1988
- Rapid colormetric assay for cell viability: Application to the quantitation of cytotoxic and growth inhibitory lymphokinesJournal of Immunological Methods, 1984